Number of patients | 48 |
Gender | |
 Male | 32 |
 Female | 16 |
 Unknown Gender | 0 |
Histological subtype | |
 Adenocarcinoma | 23 |
 Squamous-cell carcinoma | 25 |
Age | |
 Mean | Median age at diagnosis (years) | 64.65 | 64 |
 Range (years) | 44–83 |
OS | |
 Deceased | 34 |
 Alive | 14 |
 Range (months) | 2.13–78,7 |
 Median | Mean OS (months) | 30.78 | 27.27 |
PFS | |
 Deceased | 35 |
 Alive | 13 |
 Range (months) | 0.9–31.77 |
 Median | Mean PFS (months) | 9.91 | 5.52 |
RECIST | |
 Partial response | 18 |
 Stable disease | 11 |
 Progressive disease | 19 |
PD-L1 status | |
 TPS > 1% | 29 |
 TPS < 1% | 13 |
Treatment before immunotherapy | |
 Range (previous therapy lines) | 2–7 |
 Chemotherapy (first-line) | 48 |
 Radiation therapy in addition to chemotherapy | 28 |
ECOG Performance Status | |
 ECOG = 0 | 1 |
 ECOG = 1 | 33 |
 ECOG = 2 | 12 |
 ECOG > 2 | 0 |
Immune-related adverse effects | |
 Patients affected by irAE | 16 |
 Grade 1 irAE | 6a |
 Grade 2 irAE | 8a |
 Grade 3 irAE | 7a |